Soy isoflavone genistein attenuates the efficacy of immune checkpoint therapy in C57BL/6 mice inoculated with B16F1 melanoma and a high PD-‍L1 expression level reflects tumor resistance

DOI Web Site 被引用文献1件 参考文献36件
  • Yamamoto Mako
    Department of Public Health and Applied Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Tanaka Yuko
    Department of Public Health and Applied Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Takeda Risako
    Department of Public Health and Applied Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Nakamoto Akiko
    Department of Public Health and Applied Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Nakamoto Mariko
    Department of Public Health and Applied Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Yagita Hideo
    Department of Immunology, School of Medicine, Juntendo University
  • Sakai Tohru
    Department of Public Health and Applied Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School

説明

<p>Immune checkpoint therapy has been shown to be an effective therapy for many types of tumors. Much attention has been paid to the development of an effector target would be helpful for immune checkpoint therapy. Genistein has been shown to have an anti-tumor effect both in vitro and in vivo. In this study, we examined the effect of genistein on immune checkpoint blockade therapy against B16F1 melanoma tumors. Mice treated with genistein or anti-programmed death (PD)-1 antibody showed a significant decrease in tumor growth. However, treatment with genistein had no effect on or attenuated the efficacy of immune checkpoint therapy. The percentages of T cell receptor (TCR)β+CD4+ and TCRβ+CD8+ cells and the concentrations of interferon-γ and tumor necrosis factor-α in tumor tissue were not different among the experimental groups. A significant difference was also not found in microbe composition. Interestingly, a high expression level of PD-ligand (L)1 closely reflected the outcome of therapy by ‍genistein or anti-PD-1 antibody. The study showed that a combination of genistein treatment does not improve the effect of immune blockade therapy. It also showed that a high PD-L1 expression level in tumors is a good prediction maker for the outcome of tumor therapy.</p>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (36)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ